GPCR Structure Therapeutics Inc.
$21.94▲ +2.14%
Healthcare
Other
Volume 929.4K
Avg Volume (10D) 951.9K
Key Metrics & Fundamentals
Market Cap
$1.56B
P/E Ratio
–
Div Yield
0.00%
52W Range
20.50 - 94.90
% vs 50 MA
-35.49%
% vs 200 MA
-55.56%
RSI-14
26.7
MACD Histogram
+0.5900
Beta (1Y vs SPY)
1.09
Free Cash Flow
-$120.07M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$118.08M
COGS
–
Operating Exp
$118.63M
Operating Income
-$118.63M
EBIT
-$118.63M
Pretax Income
-$105.93M
Net Income
-$106.16M
EPS (Diluted)
-1.47
Price & Volume History
Loading chart…
Recent News
Buy, Sell or Hold LLY Stock? Key Factors to Watch Ahead of Q3 Earnings
Zacks · Oct 27, 2026 7:53 AM ET
How Will Novo's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Zacks · Oct 21, 2026 9:20 AM ET
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026
GlobeNewswire · Oct 19, 2026 4:13 PM ET
How Will Eli Lilly's GLP-1 Portfolio Sales Aid Upcoming Q3 Results?
Zacks · Oct 19, 2026 9:15 AM ET
Structure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset Base
Simply Wall St. · Oct 16, 2026 11:23 PM ET
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Zacks · Oct 12, 2026 11:24 AM ET
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
Zacks · Oct 8, 2026 7:31 AM ET
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Zacks · Sep 30, 2026 8:17 AM ET
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Zacks · Sep 23, 2026 10:11 AM ET
Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results
24/7 Wall St. · Sep 22, 2026 1:20 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GPCR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.